Publication Date
8-1-2024
Journal
Vaccines
DOI
10.3390/vaccines12080870
PMID
39203996
PMCID
: PMC11359273
PubMedCentral® Posted Date
8-1-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Chagas, vaccine, new treatments
Abstract
Chagas disease (CD) treatment and vaccine development are critical due to the significant health burden caused by the disease, especially in Latin America. Current treatments include benznidazole and nifurtimox, which are most effective in the acute phase of the disease but less so in the chronic phase, often with significant side effects. Here, using the available literature, we summarize the progress in vaccine development and new treatments that promise to reduce CD incidence and improve the quality of life for those at risk, particularly in endemic regions. New treatment options, such as posaconazole and fexinidazole, are being explored to improve efficacy and reduce adverse effects. Vaccine development for CD remains a high priority. The complex life stages and genetic diversity of Trypanosoma cruzi present challenges, but several promising vaccine candidates are under investigation. These efforts focus on stimulating a protective immune response through various innovative approaches.
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Diseases Commons, Influenza Humans Commons, Influenza Virus Vaccines Commons, Pediatrics Commons, Tropical Medicine Commons